CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - TSX:CPH - CA17253X1050 - Common Stock
13.5 CAD
-0.17 (-1.24%)
Taking everything into account, CPH scores 5 out of 10 in our fundamental rating. CPH was compared to 32 industry peers in the Pharmaceuticals industry. While CPH has a great profitability rating, there are some minor concerns on its financial health. CPH is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
CPH had positive earnings in the past year.
In the past year CPH had a positive cash flow from operations.
In the past 5 years CPH has always been profitable.
Each year in the past 5 years CPH had a positive operating cash flow.
1.2 Ratios
CPH has a Return On Assets of 7.98%. This is amongst the best in the industry. CPH outperforms 87.50% of its industry peers.
CPH's Return On Equity of 11.13% is amongst the best of the industry. CPH outperforms 87.50% of its industry peers.
CPH's Return On Invested Capital of 5.20% is fine compared to the rest of the industry. CPH outperforms 78.13% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CPH is in line with the industry average of 7.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.98% | ||
| ROE | 11.13% | ||
| ROIC | 5.2% |
ROA(3y)22.24%
ROA(5y)18.4%
ROE(3y)26.01%
ROE(5y)22.38%
ROIC(3y)8.41%
ROIC(5y)14.91%
1.3 Margins
Looking at the Profit Margin, with a value of 25.49%, CPH belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
CPH's Profit Margin has improved in the last couple of years.
CPH's Operating Margin of 20.32% is amongst the best of the industry. CPH outperforms 84.38% of its industry peers.
CPH's Operating Margin has declined in the last couple of years.
CPH has a Gross Margin of 73.79%. This is amongst the best in the industry. CPH outperforms 93.75% of its industry peers.
CPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.32% | ||
| PM (TTM) | 25.49% | ||
| GM | 73.79% |
OM growth 3Y-26.61%
OM growth 5Y-14.41%
PM growth 3Y0.56%
PM growth 5Y20.04%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CPH is creating some value.
CPH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CPH has less shares outstanding
CPH has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.84 indicates that CPH is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 4.84, CPH belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
CPH has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, CPH is in line with its industry, outperforming 53.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.84 |
ROIC/WACC0.66
WACC7.87%
2.3 Liquidity
A Current Ratio of 1.72 indicates that CPH should not have too much problems paying its short term obligations.
CPH has a Current ratio (1.72) which is comparable to the rest of the industry.
CPH has a Quick Ratio of 1.41. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
CPH's Quick ratio of 1.41 is in line compared to the rest of the industry. CPH outperforms 53.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
The earnings per share for CPH have decreased strongly by -48.31% in the last year.
CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 114.76%.
CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)-48.31%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%83.33%
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
3.2 Future
Based on estimates for the next years, CPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.16% on average per year.
The Revenue is expected to grow by 21.67% on average over the next years. This is a very strong growth
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.77, CPH is valued on the expensive side.
81.25% of the companies in the same industry are more expensive than CPH, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 25.46. CPH is around the same levels.
CPH is valuated correctly with a Price/Forward Earnings ratio of 14.66.
75.00% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 35.39. CPH is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.77 | ||
| Fwd PE | 14.66 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as CPH.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 15.57 |
4.3 Compensation for Growth
CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has a very decent profitability rating, which may justify a higher PE ratio.
CPH's earnings are expected to grow with 13.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.54
PEG (5Y)1.6
EPS Next 2Y19.46%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (11/19/2025, 7:00:00 PM)
13.5
-0.17 (-1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap341.82M
Revenue(TTM)47.59M
Net Income(TTM)12.13M
Analysts77.5
Price Target18.26 (35.26%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.48%
Min EPS beat(2)-7.18%
Max EPS beat(2)36.14%
EPS beat(4)1
Avg EPS beat(4)-25.25%
Min EPS beat(4)-92.76%
Max EPS beat(4)36.14%
EPS beat(8)5
Avg EPS beat(8)61.68%
EPS beat(12)9
Avg EPS beat(12)108.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-0.23%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)2.48%
Revenue beat(8)3
Avg Revenue beat(8)6.68%
Revenue beat(12)3
Avg Revenue beat(12)0.57%
Revenue beat(16)3
Avg Revenue beat(16)-2.32%
PT rev (1m)2.17%
PT rev (3m)13.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-31.15%
EPS NY rev (3m)0.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)4.34%
Revenue NY rev (3m)1.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.77 | ||
| Fwd PE | 14.66 | ||
| P/S | 5.12 | ||
| P/FCF | N/A | ||
| P/OCF | 11.42 | ||
| P/B | 2.24 | ||
| P/tB | 14.33 | ||
| EV/EBITDA | 15.57 |
EPS(TTM)0.65
EY4.81%
EPS(NY)0.92
Fwd EY6.82%
FCF(TTM)-3.25
FCFYN/A
OCF(TTM)1.18
OCFY8.76%
SpS2.64
BVpS6.04
TBVpS0.94
PEG (NY)0.54
PEG (5Y)1.6
Graham Number9.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.98% | ||
| ROE | 11.13% | ||
| ROCE | 7.22% | ||
| ROIC | 5.2% | ||
| ROICexc | 5.68% | ||
| ROICexgc | 22.71% | ||
| OM | 20.32% | ||
| PM (TTM) | 25.49% | ||
| GM | 73.79% | ||
| FCFM | N/A |
ROA(3y)22.24%
ROA(5y)18.4%
ROE(3y)26.01%
ROE(5y)22.38%
ROIC(3y)8.41%
ROIC(5y)14.91%
ROICexc(3y)14.82%
ROICexc(5y)25.77%
ROICexgc(3y)32.33%
ROICexgc(5y)N/A
ROCE(3y)11.68%
ROCE(5y)20.71%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.06%
ROICexc growth 5Y-33.64%
OM growth 3Y-26.61%
OM growth 5Y-14.41%
PM growth 3Y0.56%
PM growth 5Y20.04%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.49 | ||
| Cap/Depr | 1131.26% | ||
| Cap/Sales | 168.05% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 127.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | 4.84 |
F-Score5
WACC7.87%
ROIC/WACC0.66
Cap/Depr(3y)669.84%
Cap/Depr(5y)414.47%
Cap/Sales(3y)80.28%
Cap/Sales(5y)48.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%83.33%
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y-12.36%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.35%
EBIT Next Year136.76%
EBIT Next 3Y37.74%
EBIT Next 5YN/A
FCF growth 1Y-555.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.92%
OCF growth 3Y13.14%
OCF growth 5Y20.32%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
Can you provide the ChartMill fundamental rating for CIPHER PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to CPH.CA.
What is the valuation status of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
How profitable is CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 7 / 10.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 4 / 10.